Pathogenesis of inclusion body myositis: Autoimmune or degenerative disease?

Brain and Nerve

Volumn 65, Issue 11, 2013, Pages 1291-1298

  Uruha, Akinori ^a   Nishino, Ichizo ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Aging; CD8 positive t cell; Interleukin 1 ; Protein aggregates

Indexed keywords

AMYLOID BETA PROTEIN; AUTOANTIBODY; CYTOSOLIC 5 NUCLEOTIDASE 1A; INTERLEUKIN 1BETA; NITRIC OXIDE; PROTEIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CELL STRESS; DEGENERATIVE DISEASE; GENE OVEREXPRESSION; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; INCLUSION BODY MYOSITIS; PARKINSON DISEASE; REVIEW; SKELETAL MUSCLE;

AGING; AMYLOID BETA-PEPTIDES; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; MYOSITIS, INCLUSION BODY;

EID: 84888049936     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Suzuki N, Aoki M, Mori-Yoshimura M, Hayashi YK, Nonaka I, et al: Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 259: 554-556, 2012
2. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, et al: Intraveneous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58: 326, 2002
3. Derk CT, Vivino FB, Kenyon L, Mandel S: Inclusion body myositis in connective tissue disorders: case report and review of the literature. Clin Rheumatol 22: 324-328, 2003
4. Rojana-udomsart A, Needham M, Luo YB, Fabian V, Walters S, et al: The association of sporadic inclusion body myositis and Sjögren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 113: 559-563, 2011
5. Nogalska A, Terracciano C, D'Agostino C, King Engel W, Askanas V: p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 118: 407-413, 2009
6. Brain Nerve 63: 1205-1215, 2011
7. Clin Neurosci 30: 313-316, 2012
8. Koffman BM, Rugiero M, Dalakas MC: Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21: 115-117, 1998
9. Amato AA, Barohn RJ: Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 80: 1186-1193, 2009
10. Pruitt JN 2nd, Showalter CJ, Engel AG: Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 39: 139-143, 1996
11. Dalakas MC: Review: An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 37: 226-242, 2011
12. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, et al: Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 97: 2905-2910, 1996
13. Murata K, Dalakas MC: Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155: 453-460, 1999
14. Wiendle H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, et al: Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126: 1026-1035, 2003
15. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF: Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28: 659-682, 2003
16. Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55: 342-347, 1996
17. Confalonieri P, Bernasconi P, Megna P, Galbiati S, Cornelio F, et al: Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 59: 164-169, 2000
18. Raju R, Vasconcelos O, Granger R, Dalakas MC: Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol141: 125-131, 2003
19. Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier JF, et al: Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 31: 70-79, 2005
20. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bähr M, et al: Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 131: 1228-1240, 2008
21. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, et al: Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol 73: 397-407, 2013
22. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, et al: Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 73: 408-418, 2013
23. Schmidt J, Barthel k, Zschüntzsch J, Muth IE, Swindle EJ, et al: Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β- induced accumulation of β-amyloid and cell death. Brain 135: 1102-1114, 2012
24. Askanas V, Engel WK, Alvarez RB, Glenner GG: beta-Amyloid protein immunoreactivity in muscles of patients with inclusion-body myositis. Lancet 339: 560-561, 1992
25. Askanas V, Alvarez RB, Engel WK: beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 34: 551-560, 1993
26. Mirabella M, Alvarez RB, Bilak M, Engel WK, Askanas V: Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 55: 774-786, 1996
27. Askanas V, Engel WK, Alvarez RB, McFrrin J, Broccolini A: Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 59: 592-598, 2000
28. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, et al: TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 79: 1186-1189, 2008
29. Yamashita S, Kimura E, Tawara N, Sakaguchi H, Nakama T, et al: Optineurin is potentially associated with TDP-43 and involved in the pathogenesis of inclusion body myositis. Neuropathol Appl Neurobiol 39: 406-416, 2013
30. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB: beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 4: 815-818, 1993
31. Tanaka S, Shiojiri S, Takahashi Y, Kitaguchi N, Ito H, et al: Tissue-specific expression of three types of beta-protein precursor mRNA: enhancement of protease inhibitor-harboring types in Alzheimer's disease brain. Biochem Biophys Res Commun 165: 1406-1414, 1989
32. Vattemi G, Engel WK, McFerrin J, Buxbaum JD, Pastorino L, et al: Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 358: 1962-1964, 2001
33. Wojcik S, Engel WK, Yan R, McFerrin J, Askanas V: NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and A beta PP-overexpressing cultured human muscle fibers. Acta Neuropathol 114: 517-526, 2007
34. Nogalska A, Engel WK, Askanas V: Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers: possibly caused by endoplasmic reticulum stress. Neurosci Lett 474: 140-143, 2010
35. Askanas V, Engel WK, Nogalska A: Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 19: 493-506, 2009
36. Askanas V, Engel WK, Nogalska A: Pathogenic considerations in sporadic inclusi on-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 71: 680-693, 2012
37. Wilczynski GM, Engel WK, Askanas V: Association of active extracellular signal-regulated protein kinase with paired helical filaments of inclusion-body myositis muscle suggests its role in inclusion-body myositis tau phosphorylation. Am J Pathol 156: 1835-1840, 2000
38. Wilczynski GM, Engel WK, Askanas V: Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation. Neurosci Lett 293: 33-36, 2000
39. Kannanayakal TJ, Mendell JR, Kuret J: Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett 431, 141-145, 2008
40. Terracciano C, Nogalska A, Engel WK, Askanas V: In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 112: 389-396, 2010
41. Benilova I, Karran E, De Strooper B: The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15: 349-357, 2012
42. Nogalska A, D'Agostino C, Engel WK, Askanas V: Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 120: 661-666, 2010
43. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L: Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 10: 1015-1025, 2011
44. Crews L, Tsigelny I, Hashimoto M, Masliah E: Role of synucleins in Alzheimer's disease. Neurotox Res 16: 306-317, 2009
45. Devi L, Anandatheerthavarada HK: Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta 1802: 11-19, 2010
46. Ferrer I, Martin B, Castaño JG, Lucas JJ, Moreno D, et al: Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 63: 484-498, 2004
47. Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, et al: Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 167: 517-526, 2005
48. Nogalska A, D'Agostino C, Terracciano C, Engel WK, Askanas V: Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J pathol 177: 1377-1387, 2010
49. Schmid D, Münz C: Localization and MHC class II presentation of antigens targeted for macroautophagy. Methods Mol Biol 445: 213-225, 2008
50. Kitazawa M, Green KN, Caccamo A, LaFerla FM: Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 168: 1986-1997, 2006
51. Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, et al: Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci U S A 106: 11125-11130, 2009
52. Engel T, Goñi-Oliver P, Gómez de Barreda E, Lucas JJ, Hermández F, et al: Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis 5: 247-249, 2008
53. Kitazawa M, Trinh DN, LaFerla FM: Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 64: 15-24, 2008
54. Benveniste O, Hilton-Jones D: International Workshop on inclusion body myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 20: 414-421, 2010